Celltrion USA announced the launch of an 80mg dose of YUFLYMA® (adalimumab-aaty), a high-concentration (100mg/mL) and citrate-free formulation of HUMIRA® (adalimumab) biosimilar, in the United States.
YUFLYMA is currently available in a single 40 mg dose in both a prefilled syringe with safety guard and autoinjector. The addition of an 80 mg dose will offer more choice and dosage flexibility for patients and clinical practices. YUFLYMA 80 mg is offered at the same price as YUFLYMA 40 mg to meet the needs of patients, prescribers, and payers. In addition, a 20 mg dose of YUFLYMA is expected to be available in pharmacies in late Q1 2024.
More than 80% of patients treated with HUMIRA in the U.S. rely on a high-concentration and citrate-free formulation. YUFLYMA is a citrate-free formulation that is highly concentrated at 100mg/mL. It also maintains stability at 25℃ (77°F) for 31 days, with protection from light, and is a latex-free device.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!